Influenza Surveillance
Vaccine Recommendations
Samples Received
Surveillance Data


Contact
WHO Collaborating Centre for Reference and Research on Influenza (VIDRL)
Peter Doherty Institute for Infection and Immunity
792 Elizabeth Street
Melbourne VIC 3000 Australia

T +61 3 9342 9300
F +61 3 9342 9329
whoflu@influenzacentre.org


Current Vaccine Recomendations

9 October 2018

2019 WHO Southern Hemisphere recommendations

It is recommended that egg-based quadrivalent vaccines for use in the 2019 influenza season (southern hemisphere winter) contain the following:

  •   an A/Michigan/45/2015 (H1N1)pdm09-like virus;
  •   an A/Switzerland/8060/2017 (H3N2)-like virus;
  •   a B/Colorado/06/2017-like virus (B/Victoria/2/87 lineage); and
  •   a B/Phuket/3073/2013-like virus (B/Yamagata/16/88 lineage).
It is recommended that egg-based trivalent vaccines for use in the 2019 influenza season (southern hemisphere winter) contain the following:
  •   an A/Michigan/45/2015 (H1N1)pdm09-like virus;
  •   an A/Switzerland/8060/2017 (H3N2)-like virus; and
  •   a B/Colorado/06/2017-like virus (B/Victoria/2/87 lineage).
It is recommended that the A(H3N2) component of non-egg based vaccines for use in the 2019 southern hemisphere influenza season be an A/Singapore/INFIMH-16-0019/2016-like virus together with the other vaccine components as indicated above.

Full WHO Recommendation


27 February 2018

2018-19 WHO Northern Hemisphere recommendations

It is recommended that quadrivalent vaccines for use in the 2018-2019 influenza season (northern hemisphere winter) contain the following:

  •   an A/Michigan/45/2015 (H1N1)pdm09-like virus;
  •   an A/Singapore/INFIMH-16-0019/2016 (H3N2)-like virus;
  •   a B/Colorado/06/2017-like virus (B/Victoria/2/87 lineage); and
  •   a B/Phuket/3073/2013-like virus (B/Yamagata/16/88 lineage).

It is recommended that the influenza B virus component of trivalent vaccines for use in the 2018-2019 northern hemisphere influenza season be a B/Colorado/06/2017-like virus of the B/Victoria/2/87-lineage.

Full WHO Recommendation


16 October 2018

Australian Influenza Vaccine Committee (AIVC) decision on the influenza vaccine virus composition for Australia in 2019

The AIVC met on 10 October 2018 and recommended that the following viruses be used for influenza vaccines in the 2019 southern hemisphere influenza season:

Egg based quadrivalent vaccines:

  • an A/Michigan/45/2015 (H1N1)pdm09-like virus;
  • an A/Switzerland/8060/2017 (H3N2)-like virus;
  • a B/Colorado/06/2017-like virus (B/Victoria/2/87 lineage); and
  • a B/Phuket/3073/2013-like virus (B/Yamagata/16/88 lineage)

Egg based trivalent vaccines:

  • an A/Michigan/45/2015 (H1N1)pdm09-like virus;
  • an A/Switzerland/8060/2017 (H3N2)-like virus; and
  • a B/Phuket/3073/2013-like (B/Yamagata/16/88 lineage)

Non-egg based vaccines:

  • A(H3N2) component: A/Singapore/INFMH-16-0019/2016 (H3N2)-like virus
  • other components the same as above indicated for egg based vaccines

See the TGA website for further information.